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Risk Factors for Acute Rejection in 806 Cyclosporine-Treated Renal
Transplants: A Multivariate Analysis
A. Mota, A. Figueiredo, M.F.X. Cunha, M. Bastos, J. Pratas, and L. Furtado
IT is known that acute rejection (AR) is responsible forserious graft injury, causing parenchymal deterioration
that can end in early graft failure1 or in long-term develop-
ment of chronic dysfunction.2 Both mechanisms contribute
negatively to graft survival.3,4 The aim of this study was to
investigate the incidence, the causes, and the effects of AR
on the outcome of transplants under cyclosporine (CyA)-
based therapy.
PATIENTS AND METHODS
We analyzed 866 renal transplants performed between December
1985 and December 1999: of these, 854 (98.6%) were from
cadaveric (834 primary transplants and 20 retransplants) and 12
(1.4%) were from living related donors. Acute rejection was
biopsy-proven in 35%; in 65% it was diagnosed by clinical and
laboratory elements, among which the most relevant was a serum
creatinine (SCr) increase of at least 0.4 mg/dL. Sixty transplants
were not included, either because the diagnosis of AR was not
available or because nonimmunologic causes, such as vascular
thrombosis or death, were responsible for the early graft loss.
Therefore, 806 renal transplants (794 from cadaveric and 12 from
living donor) remained eligible for the study. Steroid-based therapy
was the AR treatment of choice. Antibody therapy was used for
steroid-resistant AR. A diagnosis of chronic dysfunction (CD) was
based on a progressive decline of renal function with a SCr 2.5
mg/dL.
We investigated the following parameters: namely in the donor
(age, cause of death, perfusion solution, cold ischemia time [CIT],
and SCr before retrieval), in the recipient (age, weight, associated
pathology, HLA mismatches, and immunosuppression), and in the
transplant course (delayed graft function [DGF], SCr at the end of
the first year, and CD). Evaluation of transplant variables included
the influence of DGF on AR incidence and, in contrast, the
influence of AR on the SCr in the first year and on CD occurrence.
We did not consider sensitization because the panel reactive
antibody (PRA) rate proved to be irrelevant (2%). The cytomeg-
alovirus status was not available. From database constructed with
the records of all donors and recipients, a multivariate analysis was
performed using logistic regression and univariate techniques with
the Fisher Exact Test. We used the Kaplan-Meier method to
calculate survival and the log-rank test to compare survival rates
between the two groups (with AR or without AR). For all tests a P
value .05 was considered significant (two-tailed).
RESULTS
Acute rejection was diagnosed in 300 (37%) of the 806
renal transplants. A multivariate analysis showed that the
risk factors for AR were cerebrovascular stroke as a cause
of death in the cadaver donor (54% vs 35%), graft perfusion
with Euro-Collins solution (42% vs 33%), cold ischemia
time (CIT)24 hours (44% vs 34%), and recipient age45
years (42% vs 30%) (Table 1). The difference in the
incidence of AR between the groups with 6, 5, 4 versus 3, 2,
1 HLA mismatches was not significant (39% vs 35%). The
quadruple immunosuppressive regimen of antilymphocyte
globulin (ALG)  azathioprine (Aza)  prednisone (Pred)
 CyA was associated with the highest (46%) incidence of
AR, and micophenolate mofetil (MMF) CyA Pred, the
lowest (30%) risk. Acute rejection was more frequent
among patients with DGF (48% vs 35%), and AR was
responsible for 4.7% of graft losses (11 grafts of 236).
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Regarding the influence of AR on transplant evolution
(Table 2), we observed significantly worse renal function at
1 year evaluated as a SCr 1.2 mg/dL, namely 46% vs 27%,
and a higher CD incidence, namely 40% vs 12%. This
higher CD incidence is particularly important because CD
emerged as the second cause of graft failure, with a rate of
30.5%, after death with a functioning graft (DWFG),
namely 41.5%.
Graft survival rates at 1, 3, 5, 10, and 15 years were 94%,
85%, 74%, 49%, and 37% in the AR group, respectively,
and 97%, 91%, 88%, 77%, and 68% in the group without
AR, respectively. The differences in graft survival were
statistically significant (P  .000) (Fig 1). Acute rejection
did not influence patient survival (P  .914). These survival
results did not include grafts and patients who had been lost
due to nonimmunologic causes (vascular thrombosis and
death), before reaching 6 months’ survival.
DISCUSSION
The progress of immunosuppression has dramatically changed
the incidence and consequences of AR. Therefore, graft loss
secondary to AR has become quite uncommon. Despite this
progress, the role of AR in the development of CD is
incontrovertible,1 and CD appears to be one of the principal
causes of graft failure. Ferguson et al5 showed that the number
of AR episodes was the most relevant factor for long-term
cadaver kidney allograft outcome, and Matas6 emphasized
that one AR episode is enough to decrease long-term graft
survival. In the present study, AR was responsible for only
4.7% of graft loss, but CD emerged as the second cause of
graft failure, with a 30.5% rate. Our results (Table 2) clearly
show that AR was the most important factor for CD (12%
without AR vs 40% with AR). The AR immunological dam-
age promotes a local cytokine release, inducing progressive
nephron damage and renal mass destruction, with develop-
ment of a fibrotic repair that ends in CD.2 Hyperfiltration in
the remnant nephrons, leading to glomerulosclerosis, also
plays a role in the evolution to organ failure.2,4 Basadonna et
al7 showed a CD occurrence of less than 1% at 5 years without
AR and about 50% with previous AR.
Concerning the increase in AR among grafts from ca-
daver donors whose cause of death was cerebrovascular
stroke with a prolonged history of arterial hypertension,
Guidi et al8 reported that a grafted kidney from a hyper-
tensive donor could transmit not only chronic hypertension,
but also more severe kidney impairment after an acute
insult (Table 1). It has been reported that perfusion with
Euro-Collins solution and prolonged cold ischemia times
are associated with an easier development of ischemia-
reperfusion lesions that increase both graft immunogenicity
and the rate of AR.4
The higher AR rate that we observed in younger recipi-
ents (45 years) probably indicates a stronger innate
immune responsiveness in these patients.3 Confirming this
hypothesis, Cecka observed that, in young patients, immu-
nologic graft failures were more frequent.1 Like others9 we
did not find any statistically significant difference (P .292)
between the two groups based upon the number of HLA
mismatches (6, 5, 4 vs 3, 2, 1) under CyA-based therapy.
The immunosuppressive protocol that showed a higher AR
incidence was the association of ALG  Aza  Pred 
CyA, a protocol that sought to decrease DGF incidence by
avoiding early CyA nephrotoxicity. Therefore, CyA admin-
istration was delayed until onset of diuresis. However, when
CyA was initiated and ALG was stopped, we noted a high
AR incidence (46%), despite 2 days of concomitant ther-
apy. Another finding in our study was the increase of AR
among patients with DGF (Table 1) an observation attrib-
uted to the increase graft immunogenicity, caused by DGF
Table 1. Risk Factors for Acute Rejection
Factors P Value Odds Ratio CI 95%
Donor age NS
Donor cause of death (CVS) .018 1.813 1.108–2.966
Perfusion with Euro-Collins solution .007 1.508 1.118–2.033
CIT .039 1.398 1.017–1.922
Recipient age 45 years .000 1.871 1.366–2.562
Recipient weight NS
Recipient-associated pathology NS
HLA mismatches NS
ALG  Aza  Pred  CyA .004 2.017 1.248–3.258
DGF .008 1.714 1.162–2.527
Abbreviations: CVS, cerebrovascular stroke; CIT, cold ischemia time; ALG,
antilymphocyte globulin; Aza, azathioprine; Pred, prednisone; CyA, cyclospor-
ine; DGF, delayed graft function.
Table 2. Influence of Acute Rejection on the Evolution
of the Transplant
Factors P Value Odds Ratio CI 95%
SCr at 1 year 1.2 mg/dL .000 2.358 1.742–3.191
Chronic dysfunction .000 4.819 3.360–6.912
Abbreviations: SCr, serum creatinine.
Fig 1. Comparison of graft actuarial survival without AR and
with AR (Kaplan-Meier method).
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wherein the ischemic tubular cells10 upregulate foreign histo-
compatibility antigen expression. Furthermore, graft function
at 1 year evaluated as a SCr 1.2 mg/dL was significantly
worse (46% vs 27%) among patients with AR (Table 2).
We conclude that acute rejection persists as an important
and complex factor leading to chronic allograft dysfunction,
being the second cause of kidney graft loss following death
with a functioning graft. In this study the most relevant
factors for AR were recipient age 45 years, immunosup-
pressive therapy without CyA, delayed graft function, per-
fusion with Euro-Collins solution, and prolonged cold
ischemia times (24 hours). The worse graft function at 1
year in patients with AR episodes heralds the later devel-
opment of chronic dysfunction.
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